Table 1 Patient, tumor and treatment characteristics
n | n% | Mean (min.-max.) | ||
|---|---|---|---|---|
Age | 68 (48–80) | |||
Fup (months) | 23 (9–47) | |||
TNM | T1cN0 | 31 | 62% | |
T2aN0 | 17 | 34% | ||
T2bN0 | 1 | 4% | ||
T2cN0 | 1 | 2% | ||
Gleason | 3+3 | 41 | 82% | |
3+4 | 9 | 18% | ||
IPSA | 8.2 (1.3–16) | |||
Prostate volume | 48 (22–110) | |||
Q-max | 13 (4–33) | |||
Residual | 87 (0–300) | |||
Risk Group | Low risk | 30 | 60% | |
Intermediate risk | 20 | 40% | ||
Position positive biopsy | Single sided | 31 | 62% | |
Double sided | 19 | 38% | ||
Count positive biopsy | 1 | 12 | 24% | |
2 | 14 | 28% | ||
3 | 9 | 18% | ||
4 | 8 | 16% | ||
5 | 5 | 10% | ||
7 | 2 | 4% | ||